Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Neovasc first quarter revenues increase 10% to $1,169,920

Neovasc Inc., today announced financial results for the three months ended March 31, 2011 and advances in its product development programs.

20 Jun 2011

Australian Government announces new tax credit system for R&D activities

Providing a valuable incentive for U.S. investment in Australia, the Australian Government announced an agreement under which the Parliament will enact a AU$1.8 billion R&D tax credit that will deliver funding to innovative firms in industries including advanced manufacturing, information and communications technologies, and biotechnology.

18 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

Joint venture to manufacture and distribute tenofovir gel in Africa

CONRAD and the South African Government's Technology Innovation Agency (TIA) on Tuesday announced a license agreement that grants TIA the rights to manufacture and distribute tenofovir gel in Africa, according to a CONRAD statement.

17 Jun 2011

Enterologics to acquire BioBalance from NYHC

Enterologics, Inc. announced today that it is acquiring all the shares of The BioBalance Corporation and its subsidiary BioBalance LLC from New York Health Care, Inc.

17 Jun 2011

CEVEC and Catalent Pharma Solutions offer joint cell line development service

CEVEC Pharmaceuticals, the German developer of a novel, market leading human protein expression system derived from amniocytes, and Catalent Pharma Solutions, a leading global drug development and delivery solutions provider, announced today a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.

16 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

QIAGEN to acquire Ipsogen

QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological cancers.

From QIAGEN Manchester Limited 15 Jun 2011

APP announces $38 million expansion of New York manufacturing facility

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today a $38 million expansion of its Grand Island, New York manufacturing facility.

15 Jun 2011

TIA, CONRAD enter license agreement to manufacture and distribute Tenofovir1% gel in Africa

CONRAD and the South African Government's Technology Innovation Agency (TIA) today announced a license agreement that grants TIA the rights to manufacture and distribute Tenofovir1% gel in Africa.

15 Jun 2011

Akela reports total consolidated revenues of $4.2 million for three months ended March 31, 2011

Akela Pharma, Inc., a drug development company with its lead product, Fentanyl TAIFUN, being developed for the treatment of breakthrough cancer pain and the company's wholly owned subsidiary, PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three months and year ended March 31, 2011.

15 Jun 2011

Morimatsu acquires Pharmadule

Morimatsu Industry Co., Ltd., the privately owned Japanese pioneer of tank technology, has acquired Pharmadule AB of Sweden, the world leader of modular manufacturing facilities for the pharmaceutical & biopharmaceutical industries.

14 Jun 2011

Accuray acquires TomoTherapy

Accuray Incorporated announced today that it has completed its previously announced acquisition of TomoTherapy Incorporated.

13 Jun 2011

EarlySense's new WiFi patient monitoring system receives FDA clearance and CE approval

EarlySense, which is currently bringing to market the most advanced, contact-free, patient monitoring solution for hospitals and nursing homes, announced today that it has received FDA clearance and CE approval for the new wireless (WiFi) communications component of its solution.

13 Jun 2011

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune cat allergy vaccine over a 12-week period maintained a statistically significant reduction in symptoms one year later.

13 Jun 2011